DYNE THERAPEUTICS INC
(NASDAQ: DYN)
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
28.380
-0.120
(-0.42%)
Range
27.270 - 29.000
(6.34%)
Open
-
Previous Close
28.500
Bid Price
13.190
Bid Volume
12
Ask Price
13.280
Ask Volume
9
Volume
1,321,772
Value
-
Remark
View All Events
Loading Chart...
Please login to view stock data and analysis